SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16 of the
Securities Exchange Act of 1934

For the month of May 2023

Commission File Number: 001-36349

MediWound Ltd.

(Translation of registrant's name into English)

42 Hayarkon Street
Yavne, 8122745 Israel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): __

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On May 31, 2023, MediWound Ltd. (the "Company") made available a corporate presentation on its website. A copy of the presentation is attached hereto as Exhibit 99.1. The fact that the presentation is being made available and furnished herewith is not an admission as to the materiality of any information contained in the presentation. The information contained in the presentation is being provided as of May 31, 2023 and the Company does not undertake any obligation to update the presentation in the future or to update forward-looking statements to reflect subsequent actual results.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

MEDIWOUND LTD.

Date: May 31, 2023

By: /s/ Hani Luxenburg
Name: Hani Luxenburg
Title: Chief Financial Officer

EXHIBIT INDEX

The following exhibit is filed as part of this Form 6-K:

Exhibit	Description
99.1	Corporate presentation dated May 2023


MediWound
Next-Generation Enzymatic Therapeutics
for Non-Surgical Tissue Repair
May 2023 I Nasdaq: MDWD

Cautionary Note Regarding Forward-Looking Statements

This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act and other securities laws, including but not limited to the statements related to the commercial potential of our products and product candidates, the anticipated development progress of our products and product candidates, and our expected cash runaway. In some cases, you can identify forward-looking statements by terminology such as "believe," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," "predict," "potential," or the negative of these terms or other similar expressions. Forward-looking statements are not historical facts, and are based upon management's current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management's expectations, beliefs and projections will be achieved and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Important factors that could cause such differences include, but are not limited to the uncertain, lengthy and expensive nature of the product development process; market acceptance of our products and product candidates; the timing and conduct of our studies of our product candidates; our ability to obtain marketing approval of our products and product candidates in the U.S. or other markets; our expectations regarding future growth, including our ability to develop new products; risks related to our contracts with BARDA; our ability to maintain adequate protection of our intellectual property; competition risks; and the need for additional financing. These and other significant factors are discussed in greater detail in MediWound's annual report on Form 20-F for the year ended December 31, 2022, filed with the Securities and Exchange Commission ("SEC") on March 16, 2023, and other filings with the SEC from time-to-time. These forward-looking statements reflect MediWound's current views as of the date hereof and MediWound undertakes, and specifically disclaims, any obligation to update any of these forward-looking statements to reflect a change in their respective views or events or circumstances that occur after the date of this release except as required by law

Certain studies and data presented herein have been conducted for us by other entities as indicated where relevant. Intellectual property, including patents, copyrights or trade secret displayed in this presentation, whether registered or unregistered, are the intellectual property rights of MediWound. MediWound's name and logo and other MediWound product names, slogans and logos referenced in this presentation are trademarks of MediWound Ltd. and/or its subsidiaries, registered in the U.S.A., EU member states and Israel.

NexoBrid development has been supported in part with federal funding from U.S. Biomedical Advanced Research and Development Authority (BARDA), Administration for Strategic Preparedness and Response (ASPR), within the U.S. Department of Health and Human Services (HHS), under ongoing USG Contract numbers HHSO100201500035C and HHSO100201800023C. Contract number HHSO100201500035C provides funding and technical support for the pivotal U.S. Phase 3 clinical study (DETECT) and the marketing approval registration process for NexoBrid as well as its procurement and availability under the expanded access treatment protocol (NEXT) in the U.S. Additional projects for evaluation of NexoBrid funded under the BARDA contract include randomized, controlled pivotal clinical trial for use in pediatric population, establishment of a pre-emergency use data package and development of the health economic model to evaluate the cost savings impact to enable market adoption in the United States.

We maintain our books and records in U.S. dollars and report under IFRS.

Company Highlights

Validated enzymatic technology platform

FDA/EMA/PMDA approvals
14 successful clinical trials
120+peer reviewed publications

Diversified portfolio

NexoBrid® - 2022 revenues: $26.5M
EscharEx® - **$2B*** opportunity

cGMP certified sterile manufacturing facility

Provides capacity to scale revenue growth

Global strategic partnerships

BARDA, Vericel, DoD (US), Kaken (JP), BSV (IN)

Solid balance sheet & strong investor base

Cash of ~$57M

*TAM - targeted addressable market; Source: Oliver Wyman market research

Leadership Team

Nachum (Homi) Shamir
Chairman of the Board

Luminex
GI EN IMAGING
Kodak

Ofer Gonen
Chief Executive Officer

gamida cell
CACTUS
CBI

Barry Wolfenson
EVP Strategy & Corp Dev.

DERMASCIENCES
ANDERSEN CONSULTING
Bristol Myers Squibb

Dr. Ety Klinger
Chief R&D Officer

teva
PROTEO LOGICS
TEL AVIV UNIVERSITY

Tzvi Palash
Chief Operating Officer

gamida cell
PROTALIX Biotherapeutics
Johnson & Johnson

Hani Luxenburg
Chief Financial Officer

AstraZeneca
BIRD AEROSYSTEMS
EY

Dr. Robert J. Snyder
Chief Medical Officer

Systagenix
3M
Johnson & Johnson

Clinically and Commercially Validated Protein-Based Therapies

Proprietary IP protected manufacturing process

1. Pineapple stem harvest
2. Protein extraction
3. Purification, enrichment, stabilization
4. Complex mixture of proteolytic enzymes

Images modified from Labster theory and bioinfo

Selective enzymes quickly target only non-viable tissue

Multibillion Dollar Portfolio

Commercial

NexoBrid®

Disruptive therapy for burn care

Indication: Eschar removal of deep partial and full thickness burns

Classification: Orphan biological drug

Target users: Hospitalized patients

Substantial U.S. government support

Development status: FDA/EU/JP approved

TAM* (U.S.): **>$300M**

Pipeline

EscharEx®

Next-gen enzymatic therapy for wound care**

Indication: Debridement of chronic / hard-to-heal wounds

Classification: Biological drug - optimized for outpatient setting

Development status: **Phase III ready**

TAM* (U.S.): **>$2B**

Pipeline

MW005

Biotherapy for non-melanoma skin cancers**

Indication: Treatment of non-melanoma skin cancers

Classification: Biological drug - optimized for outpatient setting

Development status: Phase I/II

TAM* (U.S.): **>$1B**

*TAM - targeted addressable market; Source: Oliver Wyman market research
**Investigational drug

Pipeline


Development
Phase I
Phase II
Phase III
Registration
Market
NexoBrid®
Burn eschar removal in adults
Approved
Pediatric indication for burns
Study completed
Expanded access protocol
On-going
Sulfur mustard injuries
BARDA funded
Battlefield treatment
DoD funded
EscharEx®
Debridement of VLUs
P3 ready – initiation in H2/2023
Debridement of VLU/DFU/post-op
P2 Study completed
Pharmacology study VLU/DFU
P2 Study completed
MW005
BCC (topical)
P1/2 On-going
MW003
Tissue disorders (injectable)
P1 ready

Upcoming Milestones



Financial Highlights

BALANCE SHEET

$57M in cash*
as of December 31, 2022

Cash runway - through profitability

High quality investor base

REVENUES

2022 revenues of **~$26.5M**
NexoBrid is profitable

2023 Product revenues
>30% growth

2023 Product **gross margin >50%**;
scale-up drives further increase

COMMERCIALIZATION

Global expansion via strategic collaborations (Vericel, Kaken, BSV, GAG)

Up to **$216M** support by BARDA

EU direct sales force; focus on EU-5 (CAGR >20%)

Nasdaq | MDWD

ANALYSTS:

- Josh Jennings, MD, Cowen
- Francois Brisebois, Oppenheimer
- Jason McCarthy, Ph.D, Maxim
- Swayampakula Ramakanth, PhD, HCW
- David Bouchey, Aegis

* Cash, cash equivalents and short-term bank deposits

NexoBrid®

Early, effective and selective non-surgical eschar removal for severe burns

Validated & commercialized	Approved in the U.S., EU, JP, IN; 12,000 patients treated globally to date

MediWound

Clear Unmet Need for **Early, Effective and Selective Non-Surgical Eschar Removal** in Severe Burns

Eschar removal is the **1st critical step in burn care**



Prevents local infection and sepsis	Avoids further deterioration and scarring	Enables initiation of wound healing	Allows visual assessment of wound bed

Current practice* is **traumatic & non-selective**



Loss of healthy tissue & blood	**Challenging in delicate areas**	**Requires surgical team, operating room**

NexoBrid®

Indicated for eschar removal of deep-partial & full-thickness thermal burns

Disruptive Bioactive Therapy for Burn Care

Significantly reduces need for surgery & improves patient outcomes



A sterile mixture of proteolytic enzymes

Effectively removes eschar within 4 hours without harming viable tissue or blood loss

Allows for early visual assessment of the wound



Easy-to-use, topical application at patient's bedside

NexoBrid® - Phase III Studies Demonstrate Superiority

Incidence of complete eschar removal



Time to complete eschar removal



Incidence of surgical eschar removal



Blood loss

No safety issues after 24 month follow-up

Non-inferiority in time to complete wound closure & scarring

Consistent with EU Phase III study & pediatrics Phase III study

EscharEx®

Next-Generation Enzymatic Debridement for Wound Care

Superior to SOC - Sets a new bar for efficacy	Targets **$2B market opportunity**	De-risked: Based on a validated technology

MediWound

Approaches in **Chronic Wound Debridement** are abundant but sub-optimal

Modalities by Efficacy and Convenience

Modalities by Wound Type (U.S.)*



EscharEx®

Targeting debridement of chronic and hard-to-heal wounds

Next-Generation Enzymatic Debridement - **Wound Bed Preparation within Days**



VLU



DFU

- Investigational drug containing a sterile mixture of proteolytic enzymes
- Debrides chronic wounds in 4-6 daily applications
- Inline with current treatment workflows and reimbursement landscape
- Easy to use, daily topical application for outpatient setting
- Extended IP protection

EscharEx® Phase II Studies - High Efficacy vs. SOC

Primary Endpoint



Incidence of complete debridement

EscharEx vs. Non-Surgical SOC

Incidence of complete debridement



Average # of applications



Time to complete debridement
EscharEx - 9 days vs. NSSOC - 59 days

Current enzymatic treatment has limited efficacy and is slow acting

EscharEx® U.S. Market Opportunity*

Market potential growth



2022 Epidemiology Estimate



Cost of treatment: 1,500-1,800$

EscharEx® anticipated to draw share from all other debridement modalities

*Source: OW Primary Research (6/2022)

EscharEx® Phase III Study in VLU Patients

STUDY OBJECTIVES

To assess safety and efficacy of EscharEx compared to Gel Vehicle in VLUs

STUDY DESIGN

A global (USA, EU, Israel), randomized, double blind, adaptive design study in patients with VLUs

Two arms: EscharEx vs. Gel Vehicle, 1:1 ratio

Sample size: 244 VLU patients, Interim assessment after 160 patients

Treatment: up to 8 applications of 24 hours each

Overall duration: up to 25 weeks

ENDPOINTS

Co-primary*:

Incidence of complete debridement

Time to wound closure

Secondary:

Time to complete debridement

Incidence of complete granulation tissue

Wound area reduction

Safety:

Safety & tolerability | Change in pain | Immunogenicity
Incidence of wound closure

(*) Co-primary endpoints are supported by Phase II data:
1. Incidence of complete debridement: 63% vs. 30% (p=0.004)
2. Time to wound bed prepared for closure: 11 days vs. 85 days (p=0.002)

MW005

Novel biotherapy for
Non-Melanoma Skin Cancer

Effective and safe topical application

BCC is the most frequently diagnosed skin cancer in the U.S.

MediWound

MW005

Novel Biotherapy for Non-Melanoma Skin Cancer

The Market

- 4.3M annual cases of Basal Cell Carcinomas diagnosed in the US
- Surgery is the SOC; topical products have high AEs & recurrence rates

The Product

- Investigational drug containing a sterile mixture of proteolytic enzymes
- Easy to use, high potency, 5-7 topical applications
- US Phase I/II study, demonstrated efficacy, safety and tolerability

Investment Highlights